Treatment Information

Back

Lung Cancer treatment details. Chemotherapy, Biologic therapy.

Service de Pneumologie, Draguignan, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Draguignan
Treatments:Chemotherapy, Biologic therapyHospital:Service de Pneumologie
Drugs:Journal:Link
Date:Jul 2012

Description:

Patients:
This phase II study involved 44 elderly advanced non-small-cell lung cancer patients with an average age of 78.2 years; 84.1% were male.

Treatment:
Patients were treated with the chemotherapy agent gemcitabine and the biologic therapy agent erlotinib, which is a small molecule inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in cell growth and survival.

Toxicities:
The most severe treatment-related toxicities included grade 3-4 weakness, anemia, and thrombocytopenia. Grade 1-2 skin reactions were also reported.

Results:
The median overall survival was 4.4 months.

Support:
This study was supported by the pharmaceutical companies Roche, Lilly, and Sanofi-Aventis.

Correspondence: Dr. Herve LeCaer; email: [email protected]



Back